Research desk · GRI · Nasdaq
GRI Stock
SEC financials, peer compare, and chart. Scores open the matching desk. Research only — not advice.
GRI BIO, INC. · Pharmaceutical Preparations
GRI BIO, INC. financial statements, chart, and peer compare from SEC filings.
GRI BIO, INC. (GRI) discovers, develops, or markets pharmaceutical products.
- Market cap
- $3.92M
- P/E
- -0.03
- Op. margin
- -9,273.00%
- Profit margin
- -7,490.00%
- FCF margin
- -8,757.00%
- ROE
- -72.86%
Related Health Care stocks: VSBC stock financials · SMMT stock financials · INBX stock financials
GRI financial statements
Each Compare name is its own block of years. Filing lines are SEC reports; P/E and price sit on that name’s TTM column only.
GRI stock peer compare
Each bar is that name’s percent vs its last TTM, on one zero line. Zero is unchanged. This ticker is the black bar.
Focus chart
Zero is unchanged vs last TTM. Every name is a percent for the metric you pick.
GRI stock peer headlines
Yahoo Finance RSS for GRI and the names in Compare.
| Ticker | Date | Headline |
|---|---|---|
| Loading headlines… | ||
GRI stock price chart
Overlays follow the Compare table.
GRI stock — research snapshot
Screen strengths and watchouts for GRI stock from the latest Misprise snapshot.
Strengths
- EPS CAGR 5Y 157.8% — earnings compounding.
- Debt/equity 0.00 — leverage looks manageable.
- Current ratio 10.30 — liquidity cushion.
Watchouts
- ROA -65.8% — muted asset returns.
- ROE -72.9% — soft equity returns.
- Operating margin -9,273.0% — thin operating cushion.
- Negative profit margin — earnings quality needs scrutiny.
- Negative FCF margin — cash generation is under pressure.
- Rev CAGR 5Y —
- Rev CAGR 3Y —
- EPS CAGR 5Y 157.8%
- EPS CAGR 3Y 69.6%
- FCF CAGR 5Y 22.4%
- FCF CAGR 3Y 110.8%
GRI stock FAQs
Short answers for GRI stock — statements, sector, and how this page is meant to be used.
What is GRI stock?
GRI BIO, INC. (GRI) discovers, develops, or markets pharmaceutical products. GRI stock sits in Health Care (Pharmaceutical Preparations), listed on Nasdaq.
Where can I find GRI BIO, INC. financial statements?
GRI BIO, INC. financial statements — income statement, balance sheet, and cash flow — are on this GRI stock page, parsed from SEC 10-K and 10-Q filings. Use Annual or Quarterly, then the statement tabs. Research only.
What happened to GRI stock?
This page is a research snapshot of GRI BIO, INC. (GRI) from the latest SEC filings in the Misprise database as of TTM. It is not a news feed or a delisting notice. Open the financial statements, chart, and peer compare below, then read the filings. Research only — not financial advice.
Does this page show the GRI stock price?
The live chart on this GRI stock page is the same TradingView chart as the screener. Statement tables use SEC filings. Any price or multiple on the TTM column is a market snapshot from the last seed, not a real-time quote. Research only.
What sector is GRI stock in?
GRI BIO, INC. is classified in Pharmaceutical Preparations, inside the Health Care sector, and trades on Nasdaq. This page is a research snapshot, not a full company profile.
How do I read GRI financial statements?
Start with this ticker’s block (TTM, then its fiscal years or quarters). Each Compare name is a separate block of its own periods — not mixed by year. A blank is a period we do not have, not a zero. Research only — not a buy or sell.
Where does the GRI statement data come from?
Income, balance sheet, and cash-flow lines are parsed from SEC company filings (10-K / 10-Q and 20-F). TTM is the last four reported quarters added together, not a separate filing. P/E, forward P/E, price, and market cap are a market quote at last seed — trailing P/E from the quote when available, otherwise last price divided by TTM EPS. They are not 10-K line items and appear on the TTM column only. Research only — not financial advice.
Where can I find the GRI income statement, balance sheet, and cash flow?
On this GRI stock page, open Financial statements and use the Income, Balance sheet, and Cash flow tabs. Growth and valuation sit under More. Filing figures are from SEC reports; valuation multiples are the market snapshot described above.
What is the Misprise Score for GRI stock?
GRI stock currently scores 5/100 (Watch / incomplete (<60)). GRI BIO, INC. scores weaker or incomplete on durable growth/quality inputs — leverage, coverage, and recent results deserve extra scrutiny. The score is a screen of quality, growth, and balance-sheet inputs — not a price target. Compare it in the Misprise screener; it is not a separate score page.
How is the GRI comparison winner decided?
Lead and Tie follow the number printed on each factor row, not a blended category score. Growth, quality, score, current ratio, and coverage: the higher figure leads. Value multiples (P/E, PEG, P/B, P/S) and debt ratios: the lower figure leads. Tie appears only when those printed numbers match. The header winner is whoever takes more of those five rows. CAGR uses the 5-year horizon and drops to 3-year only when both names report it. Research only — not a buy or sell.
What is the Anomaly Score on this GRI page?
Anomaly Score is how unusual a filing pattern is versus this company’s own history and its industry — not the same as Misprise Score. A high anomaly with a weak Misprise Score is often a noisy name. Open the anomaly detector to see the flag. Research only — not financial advice.
What does the green grant dot mean on GRI stock?
A green circle next to the title means this ticker appears in the Misprise grants calendar with a recent federal award (USASpending / SAM). Tap the dot for date, agency, and amount when available. It is a research flag only — not a buy or sell signal.
Is GRI stock a buy?
No recommendation either way. This GRI stock page organizes statements, ratios, and peers so you can do your own work. It is educational only — not advice to buy or sell GRI BIO, INC..